Jan Stap
YOU?
Author Swipe
View article: Supplementary Figure S3 from Radioprotection of <i>IDH1</i>-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198
Supplementary Figure S3 from Radioprotection of <i>IDH1</i>-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198 Open
The IDH1-mutant inhibitor AGI-5198 increases IDH-mediated NAPDH production capacity in IDH1-mutated cells.
View article: Supplementary Figure S5 from Radioprotection of <i>IDH1</i>-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198
Supplementary Figure S5 from Radioprotection of <i>IDH1</i>-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198 Open
IDH1WT/R132H cells are sensitized to metformin, compared with IDH1WT/WT cells.
View article: Supplementary Table S1 from Radioprotection of <i>IDH1</i>-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198
Supplementary Table S1 from Radioprotection of <i>IDH1</i>-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198 Open
SPSS output statistics for comparisons between survival curves from colony-formation assays.
View article: Supplementary Figure S1 from Radioprotection of <i>IDH1</i>-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198
Supplementary Figure S1 from Radioprotection of <i>IDH1</i>-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198 Open
IDH1R132H mutations reduce IDH-mediated NADPH production and radioresistance.
View article: Supplementary Figure S1 from Radioprotection of <i>IDH1</i>-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198
Supplementary Figure S1 from Radioprotection of <i>IDH1</i>-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198 Open
IDH1R132H mutations reduce IDH-mediated NADPH production and radioresistance.
View article: Supplementary Figure S2 from Radioprotection of <i>IDH1</i>-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198
Supplementary Figure S2 from Radioprotection of <i>IDH1</i>-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198 Open
D-2HG inhibits IDH-mediated NADPH production capacity, but not G6PD-mediated NADPH production capacity or IDH-mediated NADH production capacity.
View article: Supplementary Table S2 from Radioprotection of <i>IDH1</i>-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198
Supplementary Table S2 from Radioprotection of <i>IDH1</i>-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198 Open
D0, n and Dq values for survival curves from colony-formation assays after IR.
View article: Supplementary Figure S5 from Radioprotection of <i>IDH1</i>-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198
Supplementary Figure S5 from Radioprotection of <i>IDH1</i>-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198 Open
IDH1WT/R132H cells are sensitized to metformin, compared with IDH1WT/WT cells.
View article: Supplementary Table S1 from Radioprotection of <i>IDH1</i>-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198
Supplementary Table S1 from Radioprotection of <i>IDH1</i>-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198 Open
SPSS output statistics for comparisons between survival curves from colony-formation assays.
View article: Supplementary Figure S2 from Radioprotection of <i>IDH1</i>-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198
Supplementary Figure S2 from Radioprotection of <i>IDH1</i>-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198 Open
D-2HG inhibits IDH-mediated NADPH production capacity, but not G6PD-mediated NADPH production capacity or IDH-mediated NADH production capacity.
View article: Data from Radioprotection of <i>IDH1</i>-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198
Data from Radioprotection of <i>IDH1</i>-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198 Open
Isocitrate dehydrogenase 1 (IDH1) is mutated in various types of human cancer to IDH1R132H, a structural alteration that leads to catalysis of α-ketoglutarate to the oncometabolite D-2-hydroxyglutarate. In this study, we present evidence t…
View article: Supplementary Figure S4 from Radioprotection of <i>IDH1</i>-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198
Supplementary Figure S4 from Radioprotection of <i>IDH1</i>-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198 Open
IDH1MT increase ROS levels and AGI-5198 attenuates this effect.
View article: Supplementary Figure S4 from Radioprotection of <i>IDH1</i>-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198
Supplementary Figure S4 from Radioprotection of <i>IDH1</i>-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198 Open
IDH1MT increase ROS levels and AGI-5198 attenuates this effect.
View article: Data from Radioprotection of <i>IDH1</i>-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198
Data from Radioprotection of <i>IDH1</i>-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198 Open
Isocitrate dehydrogenase 1 (IDH1) is mutated in various types of human cancer to IDH1R132H, a structural alteration that leads to catalysis of α-ketoglutarate to the oncometabolite D-2-hydroxyglutarate. In this study, we present evidence t…
View article: Supplementary Table S2 from Radioprotection of <i>IDH1</i>-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198
Supplementary Table S2 from Radioprotection of <i>IDH1</i>-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198 Open
D0, n and Dq values for survival curves from colony-formation assays after IR.
View article: Supplementary Figure S3 from Radioprotection of <i>IDH1</i>-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198
Supplementary Figure S3 from Radioprotection of <i>IDH1</i>-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198 Open
The IDH1-mutant inhibitor AGI-5198 increases IDH-mediated NAPDH production capacity in IDH1-mutated cells.
View article: Ultra-soft X-ray system for imaging the early cellular responses to X-ray induced DNA damage
Ultra-soft X-ray system for imaging the early cellular responses to X-ray induced DNA damage Open
The majority of the proteins involved in processing of DNA double-strand breaks (DSBs) accumulate at the damage sites. Real-time imaging and analysis of these processes, triggered by the so-called microirradiation using UV lasers or heavy …
View article: Non-SMC Element 2 (NSMCE2) of the SMC5/6 Complex Helps to Resolve Topological Stress
Non-SMC Element 2 (NSMCE2) of the SMC5/6 Complex Helps to Resolve Topological Stress Open
The structural maintenance of chromosomes (SMC) protein complexes shape and regulate the structure and dynamics of chromatin, thereby controlling many chromosome-based processes such as cell cycle progression, differentiation, gene transcr…
View article: Dopamine induces lipid accumulation, NADPH oxidase-related oxidative stress, and a proinflammatory status of the plasma membrane in H9c2 cells
Dopamine induces lipid accumulation, NADPH oxidase-related oxidative stress, and a proinflammatory status of the plasma membrane in H9c2 cells Open
Excess catecholamine levels are suggested to be cardiotoxic and to underlie stress-induced heart failure. The cardiotoxic effects of norepinephrine and epinephrine are well recognized. However, although cardiac and circulating dopamine lev…
View article: Human mast cells capture, store, and release bioactive, exogenous IL-17A
Human mast cells capture, store, and release bioactive, exogenous IL-17A Open
IL-17A, a major proinflammatory cytokine, can be produced by a variety of leukocytes, but its exact cellular source in human inflammatory diseases remains incompletely understood. IL-17A protein is abundantly found in mast cells in human t…